Combination of Taxanes, Cisplatin and Fluorouracil as Induction Chemotherapy for Locally Advanced Head and Neck Cancer: A Meta-Analysis

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Qin, Hao ^a   Luo, Jie ^a   Zhu, Yuan Ping ^a   Xie, Hai Li ^b   Yang, Wei Qiang ^a   Lei, Wen Bin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPUTER PROGRAM; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HUMAN; INCIDENCE; INFECTION; LETHARGY; META ANALYSIS; MUCOSA INFLAMMATION; NEUTROPENIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STOMATITIS; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; MODELS, STATISTICAL; ODDS RATIO; SURVIVAL RATE; TAXOIDS;

EID: 84870915371     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051526     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Seiwert TY, Cohen EE, (2005) State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92: 1341-1348.
3. Adelstein DJ, Li Y, Adams GL, Jr Wagner H, Kish JA, et al. (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21: 92-98.
4. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, et al. (2004) Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22: 69-76.
5. Forastiere AA, Maor M, Weber RS, Pajak T, Glisson B, et al. (2006) Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx-Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy.
6. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, et al. (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88: 890-899.
7. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, et al. (1994) Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86: 265-272.
8. Harari PM, (1997) Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?. J Clin Oncol 15: 2050-2055.
9. Pignon JP, Bourhis J, Domenge C, Designe L, (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949-955.
10. Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, et al. (2004) Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 15: 1179-1186.
11. Chandana SR, Conley BA, (2009) Neoadjuvant chemotherapy for locally advanced squamous cancers of the head and neck: current status and future prospects. Curr Opin Oncol 21: 218-223.
12. Kutter J, Ozsahin M, Monnier P, Stupp R, (2005) Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma. Eur Arch Otorhinolaryngol 262: 1-7.
13. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, et al. (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101: 498-506.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
15. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17: 1-12.
16. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
17. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, et al. (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357: 1705-1715.
18. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, et al. (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357: 1695-1704.
19. Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, et al. (2005) Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23: 8636-8645.
20. Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Giron CG, et al. (2009) Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol ASCO(suppl 15): abstr 6009.
21. Horwitz SB, (1992) Mechanism of action of taxol. Trends Pharmacol Sci 13: 134-136.
22. Rowinsky EK, Cazenave LA, Donehower RC, (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259.
23. Schrijvers D, Vermorken JB, (2000) Role of taxoids in head and neck cancer. Oncologist 5: 199-208.
24. Pignon JP, Syz N, Posner M, Olivares R, Le LL, et al. (2004) Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anticancer Drugs 15: 331-340.
25. Parthan A, Posner MR, Brammer C, Beltran P, Jansen JP, (2009) Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck 31: 1255-1262.
26. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, et al. (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12: 153-159.
27. Francis PA, Kris MG, Rigas JR, Grant SC, Miller VA, (1995) Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Lung Cancer 12Suppl 1: S163-S172.
28. Yano R, Konno A, Watanabe K, Tsukamoto H, Kayano Y, et al. (2011) Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials. Int J Clin Oncol.